436
Participants
Start Date
September 30, 2002
Primary Completion Date
August 31, 2008
Study Completion Date
August 31, 2008
Sibutramine
At the baseline study visit, participants in Group 1 will be given a one month supply of 5 mg/d of sibutramine and a 1-month follow-up visit will be scheduled. After a safety evaluation at the 1-month follow-up visit, participants will have their dose of sibutramine titrated to 10 mg/d, a 1 month supply of the medication will be given to participants, and a 2-month follow-up visit will be scheduled. After a safety evaluation at the 2-month follow-up visit, participants will receive a 1 month supply of sibutramine 10 mg/d and a 3-month follow-up visit will be scheduled. At the 3-month follow-up visit, the sibutramine will be discontinued and participants will be scheduled for 4- and 5-month follow-up visits.
Behavioral Smoking Cessation Program
Both groups of participants will take part in a behavioral smoking cessation program.
University of Tennessee Health Science Center, Memphis
National Heart, Lung, and Blood Institute (NHLBI)
NIH
University of Tennessee
OTHER